| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| María Teresa Guarro Carreras, Luis Jiménez Suárez, Laura Lago García, Laura Montes Reula, Adrián Neyra Del Rosario, Francisco Acoidan Rodríguez Batista, Miguel Velasco Santos, Juan L Prados-Ojeda, Marina Diaz-Marsà, Manuel Martín-Carrasco, Antonio Cardena. Towards full recovery with lurasidone: effective doses in the treatment of agitation, affective, positive, and cognitive symptoms in schizophrenia and of dual psychosis. Drugs in context. vol 13. 2024-08-12. PMID:39131604. |
furthermore, lurasidone also shows efficacy in reducing post-psychotic depression in dual psychosis. |
2024-08-12 |
2024-08-14 |
Not clear |
| Aleksandr Reznik, Timur Syunyakov, Inessa Akhmerova, Daniil Butylin, Anastasia Vasilenko, Anton Gvozdetckii, Tagir Gizatullin, Galina Gilmanshina, Egor Golosov, Sergey Kolchev, Lidiya Linova, Daniil Miron, Aleksandr Mudrak, Igor Oleichik, Stepan Sizov, Elena Tarakanova, Olga Chesnokov. Clinical Effectiveness of Lurasidone Monotherapy in Patients with Acute Episodes of Schizophrenia and Associated Symptoms of Depression. Consortium psychiatricum. vol 3. issue 3. 2024-07-24. PMID:39044917. |
clinical effectiveness of lurasidone monotherapy in patients with acute episodes of schizophrenia and associated symptoms of depression. |
2024-07-24 |
2024-07-26 |
Not clear |
| Aleksandr Reznik, Timur Syunyakov, Inessa Akhmerova, Daniil Butylin, Anastasia Vasilenko, Anton Gvozdetckii, Tagir Gizatullin, Galina Gilmanshina, Egor Golosov, Sergey Kolchev, Lidiya Linova, Daniil Miron, Aleksandr Mudrak, Igor Oleichik, Stepan Sizov, Elena Tarakanova, Olga Chesnokov. Clinical Effectiveness of Lurasidone Monotherapy in Patients with Acute Episodes of Schizophrenia and Associated Symptoms of Depression. Consortium psychiatricum. vol 3. issue 3. 2024-07-24. PMID:39044917. |
we endeavored to evaluate the efficacy of lurasidone at doses of 40-160 mg per day on symptoms of schizophrenia associated with symptoms of depression in real clinical practice in a russian patient population. |
2024-07-24 |
2024-07-26 |
Not clear |
| Taro Kishi, Kenji Sakuma, Shun Hamanaka, Yasufumi Nishii, Nakao Iwat. Discontinuation Rate of Lurasidone and Quetiapine Extended Release in Bipolar Depression. Pharmacopsychiatry. 2024-06-19. PMID:38897219. |
discontinuation rate of lurasidone and quetiapine extended release in bipolar depression. |
2024-06-19 |
2024-06-22 |
Not clear |
| Taro Kishi, Kenji Sakuma, Shun Hamanaka, Yasufumi Nishii, Nakao Iwat. Discontinuation Rate of Lurasidone and Quetiapine Extended Release in Bipolar Depression. Pharmacopsychiatry. 2024-06-19. PMID:38897219. |
lurasidone (lur) was compared with quetiapine extended release (que-er) regarding 1-year discontinuation in patients with bipolar depression (n=317). |
2024-06-19 |
2024-06-22 |
Not clear |
| Shan Gao, Ling Fan, Zhigang Yu, Xingxing Xi. Efficacy and safety of lurasidone for schizophrenia: A systematic review and meta‑analysis of eight short‑term, randomized, double‑blind, placebo‑controlled clinical trials. Biomedical reports. vol 20. issue 6. 2024-04-29. PMID:38682090. |
the meta-analysis results demonstrated that there were no significant change in total positive and negative syndrome scale (panss) score, clinical global impression of severity (cgi-s) score and montgomery-asberg depression rating scale (madrs) between the 40 mg lurasidone group and the placebo group (p>0.05). |
2024-04-29 |
2024-05-01 |
Not clear |
| Michael Tocco, Yongcai Ma. Efficacy and Safety of Adding Lurasidone to Ongoing Therapy With Lithium or Valproate for the Treatment of an Acute Bipolar Depressive Episode: A Post Hoc Analysis of 2 Placebo-Controlled Trials. Journal of clinical psychopharmacology. 2024-04-19. PMID:38639433. |
the aim of this study was to compare the efficacy and safety profile of lurasidone combined with either lithium or valproate, in the short-term treatment of patients with bipolar depression. |
2024-04-19 |
2024-04-21 |
Not clear |
| Xue-Zhu Feng, Zhe Li, Zi-Yi Li, Ke Wang, Xuan Tan, Yu-Yu Zhao, Wei-Feng Mi, Wei-Li Zhu, Yan-Ping Bao, Lin Lu, Su-Xia L. Effectiveness and safety of second-generation antipsychotics for psychiatric disorders apart from schizophrenia: A systematic review and meta-analysis. Psychiatry research. vol 332. 2023-12-27. PMID:38150810. |
aripiprazole is the most effective treatment for bipolar mania [effect size = -0.90, 95% ci: -1.59, -0.21] and tourette's disorder [effect size = -0.80, 95% ci: -1.14, -0.45], olanzapine for bipolar depression [effect size = -0.86, 95% ci: -1.32, -0.39] and post-traumatic stress disorder [effect size = -0.98, 95% ci: -1.55, -0.41], lurasidone for depression [effect size = -0.66, 95% ci: -0.82, -0.50], quetiapine for anxiety [effect size = -1.20, 95% ci: -1.96, -0.43], sleep disorders [effect size = -1.2, 95% ci: -1.97, -0.58], and delirium [effect size = -0.36, 95% ci: -0.70, -0.03], and risperidone for obsessive-compulsive disorder [effect size = -2.37, 95% ci: -3.25, -1.49], respectively. |
2023-12-27 |
2023-12-30 |
Not clear |
| Przemysław J Danek, Władysława A Danie. The Novel Atypical Antipsychotic Lurasidone Affects Cytochrome P450 Expression in the Liver and Peripheral Blood Lymphocytes. International journal of molecular sciences. vol 24. issue 23. 2023-12-09. PMID:38069119. |
lurasidone is a novel atypical antipsychotic drug acting on dopaminergic, serotonergic and noradrenergic receptors; it is applied for the long-term treatment of schizophrenia and depression in patients with bipolar disorders. |
2023-12-09 |
2023-12-17 |
rat |
| Andrew Nierenberg, Philip Lavin, Daniel C Javitt, Richard Shelton, Michael T Sapko, Sanjay Mathew, Robert E Besthof, Jonathan C Javit. NRX-101 (D-cycloserine plus lurasidone) vs. lurasidone for the maintenance of initial stabilization after ketamine in patients with severe bipolar depression with acute suicidal ideation and behavior: a randomized prospective phase 2 trial. International journal of bipolar disorders. vol 11. issue 1. 2023-08-13. PMID:37573534. |
nrx-101 (d-cycloserine plus lurasidone) vs. lurasidone for the maintenance of initial stabilization after ketamine in patients with severe bipolar depression with acute suicidal ideation and behavior: a randomized prospective phase 2 trial. |
2023-08-13 |
2023-08-16 |
Not clear |
| Andrew Nierenberg, Philip Lavin, Daniel C Javitt, Richard Shelton, Michael T Sapko, Sanjay Mathew, Robert E Besthof, Jonathan C Javit. NRX-101 (D-cycloserine plus lurasidone) vs. lurasidone for the maintenance of initial stabilization after ketamine in patients with severe bipolar depression with acute suicidal ideation and behavior: a randomized prospective phase 2 trial. International journal of bipolar disorders. vol 11. issue 1. 2023-08-13. PMID:37573534. |
we tested the hypothesis that, after initial improvement with intravenous ketamine in patients with bipolar disorder (bd) with severe depression and acute suicidal thinking or behavior, a fixed-dose combination of oral d-cycloserine (dcs) and lurasidone (nrx-101) can maintain improvement more effectively than lurasidone alone. |
2023-08-13 |
2023-08-16 |
Not clear |
| Joseph F Goldberg, Cynthia Siu, Michael Tocco, Andrei Pikalov, Antony Loebe. The Effect of Lurasidone on Anxiety Symptoms in Patients With Bipolar Depression: A Post Hoc Analysis. The Journal of clinical psychiatry. vol 84. issue 4. 2023-06-20. PMID:37339360. |
the effect of lurasidone on anxiety symptoms in patients with bipolar depression: a post hoc analysis. |
2023-06-20 |
2023-08-14 |
Not clear |
| Masaki Kato, Takahiro Masuda, Fumiya Sano, Tadafumi Kat. The efficacy and safety of lurasidone in bipolar I depression with and without rapid cycling: A pooled post-hoc analysis of two randomized, placebo-controlled trials. Journal of affective disorders. 2023-05-28. PMID:37245552. |
the efficacy and safety of lurasidone in bipolar i depression with and without rapid cycling: a pooled post-hoc analysis of two randomized, placebo-controlled trials. |
2023-05-28 |
2023-08-14 |
Not clear |
| Masaki Kato, Takahiro Masuda, Fumiya Sano, Tadafumi Kat. The efficacy and safety of lurasidone in bipolar I depression with and without rapid cycling: A pooled post-hoc analysis of two randomized, placebo-controlled trials. Journal of affective disorders. 2023-05-28. PMID:37245552. |
the efficacy and safety of lurasidone monotherapy in patients with bipolar i depression with or without rapid cycling has not been previously investigated. |
2023-05-28 |
2023-08-14 |
Not clear |
| Martin Tarzian, Majd Soudan, Muhammed Alhajji, Mariana Ndrio, Adegbenro O Fakoy. Lurasidone for Treating Schizophrenia and Bipolar Depression: A Review of Its Efficacy. Cureus. vol 15. issue 4. 2023-05-25. PMID:37228542. |
lurasidone for treating schizophrenia and bipolar depression: a review of its efficacy. |
2023-05-25 |
2023-08-14 |
Not clear |
| William Jordan, Michael T Sapko, Richard Siegel, Jonathan Javit. NRX-101, a Rapid-Acting Anti-Depressant, Does Not Cause Neurotoxicity Following Ketamine Administration in Preclinical Models. International journal of toxicology. 2023-05-24. PMID:37226048. |
d-cycloserine (dcs) is a partial nmda agonist that, along with lurasidone, is being investigated as a treatment for depression. |
2023-05-24 |
2023-08-14 |
human |
| Michael Tocco, John W Newcomer, Yongcai Mao, Andrei Pikalo. Lurasidone and risk of metabolic syndrome: results from short and long-term studies in patients with bipolar depression. CNS spectrums. 2023-03-24. PMID:36961124. |
lurasidone and risk of metabolic syndrome: results from short and long-term studies in patients with bipolar depression. |
2023-03-24 |
2023-08-14 |
Not clear |
| Michael Tocco, John W Newcomer, Yongcai Mao, Andrei Pikalo. Lurasidone and risk of metabolic syndrome: results from short and long-term studies in patients with bipolar depression. CNS spectrums. 2023-03-24. PMID:36961124. |
this post hoc analysis assessed the effect of treatment with lurasidone on risk of mets in patients with bipolar depression. |
2023-03-24 |
2023-08-14 |
Not clear |
| Valerio Ricci, Gabriele Di Salvo, Giuseppe Main. Lurasidone in first-episode psychosis with predominant depressive symptoms: a case report. International clinical psychopharmacology. 2023-02-28. PMID:36853746. |
lurasidone is an atypical antipsychotic approved for the treatment of schizophrenia and bipolar depression. |
2023-02-28 |
2023-08-14 |
Not clear |
| María Elena Gamboa-Arancibia, Nelson Caro, Alexander Gamboa, Javier Octavio Morales, Jorge Enrique González Casanova, Diana Marcela Rojas Gómez, Sebastián Miranda-Roja. Improving Lurasidone Hydrochloride's Solubility and Stability by Higher-Order Complex Formation with Hydroxypropyl-β-cyclodextrin. Pharmaceutics. vol 15. issue 1. 2023-01-21. PMID:36678861. |
this is the case of lurasidone hydrochloride-a drug used for the treatment of schizophrenia and bipolar depression. |
2023-01-21 |
2023-08-14 |
Not clear |